Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

被引：325

作者：

Moriyama, B. ^{[1
]}

Obeng, A. Owusu ^{[2
,3
,4
]}

Barbarino, J. ^{[5
]}

Penzak, S. R. ^{[6
]}

Henning, S. A. ^{[1
]}

Scott, S. A. ^{[2
,7
]}

Agundez, J. A. G. ^{[8
]}

Wingard, J. R. ^{[9
]}

McLeod, H. L. ^{[10
]}

Klein, T. E. ^{[5
]}

Cross, S. J. ^{[11
,12
]}

Caudle, K. E. ^{[11
]}

Walsh, T. J. ^{[13
,14
,15
]}

机构：

[1] NIH, Ctr Clin, Dept Pharm, Bethesda, MD 20892 USA

[2] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA

[3] Mt Sinai Hosp, Dept Pharm, New York, NY 10029 USA

[4] Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA

[5] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[6] Univ North Texas, Dept Pharmacotherapy, Syst Coll Pharm, Ft Worth, TX USA

[7] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA

[8] Univ Extremadura, Dept Pharmacol, Caceres, Spain

[9] Univ Florida, Coll Med, Gainesville, FL USA

[10] H Lee Moffitt Canc Ctr & Res Inst, DeBartolo Family Personalized Med Inst, Div Populat Sci, Tampa, FL USA

[11] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[12] Univ Tennessee, Coll Pharm, Dept Clin Pharm, Memphis, TN USA

[13] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Med, New York, NY 10021 USA

[14] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Pediat, New York, NY 10021 USA

[15] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Microbiol & Infect Dis, New York, NY 10021 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 01期

基金：

美国国家卫生研究院;

关键词：

INFECTIOUS-DISEASES SOCIETY; INTRAVENOUS VORICONAZOLE; PLASMA-CONCENTRATIONS; 2016; UPDATE; SAFETY; PHARMACOKINETICS; GENOTYPE; EFFICACY; VARIANT; POLYMORPHISMS;

D O I：

10.1002/cpt.583

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

引用

页码：45 / 51

页数：7

共 38 条

[1] Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications [J].